Hematological Malignancy
Hematological malignancy refers to cancers that affect the blood, bone marrow, and lymphatic system, including types like leukemia and lymphoma. These conditions can disrupt normal blood cell production and function.
Relapsed or Refractory PCNSL: Emavusertib Study
We are studying the safety and effectiveness of a new oral medication, emavusertib, for patients with relapsed or refractory primary central nervous system lymphoma. This trial also explores its use alongside another treatment, ibrutinib.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Primary Central Nervous System Lymphoma (PCNSL)
Primary central nervous system lymphoma (PCNSL) is a rare type of brain cancer that originates in the lymphatic system and affects the brain and spinal cord. It can lead to neurological symptoms and requires specialized treatment.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a diagnosis of B-cell non-Hodgkin lymphoma (NHL)?
- Are you currently taking any cholesterol-lowering medications like Lipitor, Crestor, or Zocor?
- Have you had any major surgery in the last 28 days?
- Are you pregnant or breastfeeding?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Ca-4948
Emavusertib
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Vseobecna Fakultni Nemocnice V Praze
Hematology
Prague, Czechia
Institut Bergonie
Hematology
Bordeaux, France
Centre Hospitalier Regional De Marseille
Neuro-oncology
Marseille, France
Sponsor: Curis Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.